
Surrozen (SRZN) Stock Forecast & Price Target
Surrozen (SRZN) Analyst Ratings
Bulls say
Surrozen is focused on developing novel biotechnology treatments that target the Wnt pathway, with a promising pipeline of drug candidates for retinal diseases such as wet AMD and DME. The company's recent updates and preclinical data demonstrate the potential of their lead compound, SZN-8141, to effectively address the unmet need for durable and impactful treatments in retinal vascular diseases. With a strong cash balance and a partnership with Boehringer Ingelheim, Surrozen is poised for success in bringing its Wnt agonist therapies to market and establishing itself as a leader in the field.
Bears say
Surrozen is a clinical-stage biotechnology company working on drug candidates that target the Wnt pathway for tissue repair. While they have several product candidates in development, including SZN-8141 and SZN-413, the company's financials show a net loss of $242 million in 2025 and limited cash on hand. However, our negative outlook is primarily due to the potential risks associated with the success and adoption of these new treatments, as well as the possibility of unexpected toxicity or competition from other therapies. We believe that these factors could hinder the company's ability to generate significant revenue and ultimately impact the perceived value of their drugs in the market.
This aggregate rating is based on analysts' research of Surrozen and is not a guaranteed prediction by Public.com or investment advice.
Surrozen (SRZN) Analyst Forecast & Price Prediction
Start investing in Surrozen (SRZN)
Order type
Buy in
Order amount
Est. shares
0 shares